Nedaplatin versus cisplatinbased chemotherapy in the survival time of patients with nonsmall cell lung cancer

Author：                  

Publisher： Science Publishers

ISSN： 2049-9450

Source： Molecular and Clinical Oncology, Vol.3, Iss.3, 2015-01, pp. : 543-549

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study

By            

Oncology Letters, Vol. 11, Iss. 1, 2016-01 ,pp. : 299-305

Spandidos Publications

Access to resources Recommend Favorite

Expression of the copper transporters hCtr1, ATP7A and ATP7B is associated with the response to chemotherapy and survival time in patients with resected non-small cell lung cancer

By        

Oncology Letters, Vol. 10, Iss. 4, 2015-01 ,pp. : 2584-2590

Spandidos Publications

Access to resources Recommend Favorite

Tailor-made chemotherapy for non-small cell lung cancer patients

By Huang Cheng-long   Yokomise Hiroyasu   Fukushima Masakazu   Kinoshita Moritoshi  

Future Oncology, Vol. 2, Iss. 2, 2006-04 ,pp. : 289-299

Future Medicine

Access to resources Recommend Favorite

Effect of chemotherapy on quality of life in patients with non-small cell lung cancer

By Mannion Eileen   Gilmartin J.   Donnellan Paul   Keane Maccon   Waldron Dympna  

Supportive Care in Cancer, Vol. 22, Iss. 5, 2014-05 ,pp. : 1417-1428

Springer Publishing Company

Access to resources Recommend Favorite

Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer

By  

International Journal of Oncology, Vol. 46, Iss. 2, 2015-02 ,pp. : 809-817

Spandidos Publications

Access to resources Recommend Favorite